Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

Last updated: January 4, 2025
Sponsor: University of Minnesota
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gaucher Disease

Treatment

no intervention

Clinical Study ID

NCT05843552
EV
  • Ages 18-80
  • All Genders

Study Summary

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age between 18-80yrs

  • Restricted to participants who are untreated, obligate carriers and healthycontrols.

  • Participants with GD should have confirmed GD diagnosis, mutation confirmed forcarriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing.

Exclusion

Exclusion Criteria:

  • Exclude participants who have any hematological malignancy or other uncontrolledcomorbid conditions.

  • Exclude participants who are currently on therapy for their GD

  • Exclude participants who have any hematological malignancy or other uncontrolledcomorbid conditions.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: no intervention
Phase:
Study Start date:
April 30, 2023
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • University of Minnesota

    Minneapolis, Minnesota 55414
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.